Investigational drug · Phase 3
OBI-821
Also called: OBI-833
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Triple Negative Breast Cancer, Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
17
Any phase or sponsor naming "OBI-821"
First trial start
2018
Dec 5, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OBI-821", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "OBI-821" as an intervention, largest first.
- Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBCPivotal-lookingActive, not recruiting
OBI Pharma, IncIndustry
NCT03562637 · 575 participants · Start Dec 5, 2018 · Primary completion Dec 30, 2025
Drug: adagloxad simolenin combined with OBI-821 · For: Triple Negative Breast Cancer
Sites: La Jolla, California; San Diego, California; San Francisco, California · 128 sites in all
- Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk NeuroblastomaPivotal-lookingCompleted
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT00911560 · 374 participants · Start May 27, 2009 · Primary completion Aug 3, 2026
Drug: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH; oral β-glucan · For: Neuroblastoma
Sites: New York, New York
- Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer SubjectsPivotal-lookingCompleted
OBI Pharma, IncIndustry
NCT01516307 · 349 participants · Start Dec 2011 · Primary completion Aug 2016
Drug: OPT-822/OPT-821(30 μg/100 μg); Phosphate Buffer Saline (PBS) and 1 more · For: Metastatic Breast Cancer
Sites: Birmingham, Alabama; Fullerton, California; La Jolla, California · 43 sites in all
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaPivotal-lookingRecruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT04936529 · 286 participants (planned) · Start Aug 2, 2021 · Primary completion Jun 15, 2027
Drug: GM-CSF; OPT-821 · For: Neuroblastoma
Sites: New York, New York
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete RemissionPivotal-lookingCompleted
Gynecologic Oncology GroupResearch network
NCT00857545 · 171 participants · Start Jul 2010 · Primary completion Sep 2015
Drug: Polyvalent Antigen-KLH Conjugate Vaccine; Saponin-based Immunoadjuvant OBI-821 · For: Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer and 21 more
Sites: Mobile, Alabama; Orange, California; Palo Alto, California · 46 sites in all
- Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease FreePivotal-lookingCompleted
MabVax Therapeutics, Inc.Industry
NCT01141491 · 136 participants · Start Jun 2010 · Primary completion Sep 2013
Drug: Trivalent ganglioside vaccine; OPT-821 · For: Sarcoma
Sites: Los Angeles, California; Denver, Colorado; Atlanta, Georgia · 13 sites in all
- Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian CancerStatus unknown
Mackay Memorial HospitalAcademic, hospital or other
NCT02132988 · 110 participants (planned) · Start Nov 2013 · Primary completion Nov 2017
Drug: OPT-822/OPT-821 · For: Ovarian Cancer
Sites: Taipei, Taiwan
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT06057948 · 100 participants (planned) · Start Sep 21, 2023 · Primary completion Mar 21, 2027
Drug: OPT-821 (QS-21) · For: Neuroblastoma; High-risk Neuroblastoma; Metastatic Neuroblastoma
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
- To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for RecurrenceStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT05376423 · 60 participants (planned) · Start Jun 2, 2022 · Primary completion Dec 2024
Drug: OBI-833/OBI-821 · For: Esophageal Cancer
Sites: Taipei, Taiwan
OBI Pharma, IncIndustry
NCT05442060 · 60 participants (planned) · Start Jul 27, 2022 · Primary completion Dec 31, 2025
Drug: 30 μg OBI-833/100 μg OBI-821; Erlotinib (150 mg daily) · For: Non-small Cell Lung Cancer
Sites: Taipei, Taiwan; Taoyuan, Taiwan; New Taipei City, Taiwan · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Globo H ceramide confers chemoresistance and poor prognosis to advanced gallbladder cancer via A2AR/cAMP/PKA pathway.
Hung TH, Hung JT, Huang WK, et al. · Theranostics 2026
- GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
Rugo HS, Cortes J, Barrios CH, et al. · Future Oncol 2022
- The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer.
Hung JT, Chen IJ, Ueng SH, et al. · J Immunother Cancer 2022
- Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.
Huang CS, Yu AL, Tseng LM, et al. · J Immunother Cancer 2020
Also in development for Triple Negative Breast Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- FDA018-ADCPhase 31 trial
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Triple Negative Breast Cancer
- IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials
Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- BLEX 404 LiquidPhase 22 trials
BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer
- DNA VaccinePhase 22 trials
NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.